These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 27075078)

  • 21. Immunotherapy of melanoma: present options and future promises.
    Rotte A; Bhandaru M; Zhou Y; McElwee KJ
    Cancer Metastasis Rev; 2015 Mar; 34(1):115-28. PubMed ID: 25589384
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monotherapeutically nonactive CTLA-4 blockade results in greatly enhanced antitumor effects when combined with tumor-targeted superantigens in a B16 melanoma model.
    Sundstedt A; Celander M; Eriksson H; Törngren M; Hedlund G
    J Immunother; 2012 May; 35(4):344-53. PubMed ID: 22495392
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human Tumor Antigens and Cancer Immunotherapy.
    Vigneron N
    Biomed Res Int; 2015; 2015():948501. PubMed ID: 26161423
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations.
    Tran E; Robbins PF; Rosenberg SA
    Nat Immunol; 2017 Feb; 18(3):255-262. PubMed ID: 28198830
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1.
    Simeone E; Ascierto PA
    J Immunotoxicol; 2012; 9(3):241-7. PubMed ID: 22524673
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Anti-CTLA-4 monoclonal antibody: a major step in the treatment of metastatic melanoma].
    Robert C; Mateus C
    Med Sci (Paris); 2011 Oct; 27(10):850-8. PubMed ID: 22027422
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunology beats cancer: a blueprint for successful translation.
    Pardoll DM
    Nat Immunol; 2012 Dec; 13(12):1129-32. PubMed ID: 23160205
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Melanoma drug wins US approval.
    Ledford H
    Nature; 2011 Mar; 471(7340):561. PubMed ID: 21455150
    [No Abstract]   [Full Text] [Related]  

  • 29. MICROBIOME. Microbes aid cancer drugs.
    Leslie M
    Science; 2015 Nov; 350(6261):614-5. PubMed ID: 26542545
    [No Abstract]   [Full Text] [Related]  

  • 30. [New hope in metastatic melanoma treatment?].
    Guillot B
    Ann Dermatol Venereol; 2012 Oct; 139(10):693-4. PubMed ID: 23122388
    [No Abstract]   [Full Text] [Related]  

  • 31. Tremelimumab: a review of development to date in solid tumors.
    Tarhini AA
    Immunotherapy; 2013 Mar; 5(3):215-29. PubMed ID: 23444951
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MUC1 immunotherapy.
    Beatson RE; Taylor-Papadimitriou J; Burchell JM
    Immunotherapy; 2010 May; 2(3):305-27. PubMed ID: 20635898
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vaccines versus immunotherapy: overview of approaches in deciding between options.
    Dalgleish AG
    Hum Vaccin Immunother; 2014; 10(11):3369-74. PubMed ID: 25625932
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CTLA-4 blockade: autoimmunity as treatment.
    Kapadia D; Fong L
    J Clin Oncol; 2005 Dec; 23(35):8926-8. PubMed ID: 16204008
    [No Abstract]   [Full Text] [Related]  

  • 35. Targeting cytotoxic T-lymphocyte antigen 4 in immunotherapies for melanoma and other cancers.
    Page DB; Yuan J; Wolchok JD
    Immunotherapy; 2010 May; 2(3):367-79. PubMed ID: 20635901
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CIMT 2014: Next waves in cancer immunotherapy--report on the 12th annual meeting of the Association for Cancer Immunotherapy: May 6–8 2014, Mainz, Germany.
    Diken M; Boegel S; Grunwitz C; Kranz LM; Reuter K; van de Roemer N; Vascotto F; Vormehr M; Kreiter S
    Hum Vaccin Immunother; 2014; 10(10):3090-100. PubMed ID: 25483671
    [No Abstract]   [Full Text] [Related]  

  • 37. Anti-cytotoxic T-cell lymphocyte antigen-4-induced regression of spinal cord metastases in association with renal failure, atypical pneumonia, vision loss, and hearing loss.
    Voskens C; Cavallaro A; Erdmann M; Dippel O; Kaempgen E; Schuler G; Schuler-Thurner B; Heinzerling L
    J Clin Oncol; 2012 Nov; 30(33):e356-7. PubMed ID: 23045571
    [No Abstract]   [Full Text] [Related]  

  • 38. The role of the CTLA4 blockade in the treatment of malignant melanoma.
    Cranmer LD; Hersh E
    Cancer Invest; 2007 Oct; 25(7):613-31. PubMed ID: 18027152
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Advances in Cancer Therapy: Immunotherapies.
    Marmé D
    Oncol Res Treat; 2016; 39(6):324-5. PubMed ID: 27260772
    [No Abstract]   [Full Text] [Related]  

  • 40. Cancer immunotherapy: Progress and challenges in the clinical setting.
    Zarour HM; Ferrone S
    Eur J Immunol; 2011 Jun; 41(6):1510-5. PubMed ID: 21618503
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.